Empagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in routine care in East Asia: Results from the EMPRISE study

AIMS/INTRODUCTION: The EMPA‐REG OUTCOME® trial demonstrated benefits of empagliflozin, a sodium‐glucose cotransporter‐2 inhibitor (SGLT2i), on cardiovascular, renal outcomes and all‐cause mortality in patients with type 2 diabetes and established cardiovascular disease. The EMPRISE study program eva...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Dae Jung, Sheu, Wayne H‐H, Chung, Wook‐Jin, Yabe, Daisuke, Ha, Kyoung Hwa, Nangaku, Masaomi, Tan, Elise Chia‐Hui, Node, Koichi, Yasui, Atsutaka, Lei, Weiyu, Lee, Sunwoo, Saarelainen, Laura, Deruaz‐Luyet, Anouk, Kyaw, Moe H, Seino, Yutaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9951576/
https://www.ncbi.nlm.nih.gov/pubmed/36716212
http://dx.doi.org/10.1111/jdi.13959

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9951576/
https://www.ncbi.nlm.nih.gov/pubmed/36716212
http://dx.doi.org/10.1111/jdi.13959

Ejemplares similares